Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more
Werewolf Therapeutics Inc (HOWL) - Total Assets
Latest total assets as of September 2025: $79.63 Million USD
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) holds total assets worth $79.63 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Werewolf Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Werewolf Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Werewolf Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Werewolf Therapeutics Inc's total assets of $79.63 Million consist of 89.1% current assets and 10.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 87.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Werewolf Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Werewolf Therapeutics Inc's current assets represent 89.1% of total assets in 2024, an increase from 83.3% in 2019.
- Cash Position: Cash and equivalents constituted 87.5% of total assets in 2024, up from 82.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Werewolf Therapeutics Inc Competitors by Total Assets
Key competitors of Werewolf Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Werewolf Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Werewolf Therapeutics Inc generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Werewolf Therapeutics Inc is currently not profitable relative to its asset base.
Werewolf Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.87 | 10.10 | 17.58 |
| Quick Ratio | 3.87 | 10.10 | 17.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $50.57 Million | $ 113.37 Million | $ 87.63 Million |
Werewolf Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Werewolf Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.11 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -27.4% |
| Total Assets | $126.93 Million |
| Market Capitalization | $34.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Werewolf Therapeutics Inc's assets below their book value (0.27 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Werewolf Therapeutics Inc's assets decreased by 27.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Werewolf Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Werewolf Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $126.93 Million | -27.40% |
| 2023-12-31 | $174.83 Million | +9.10% |
| 2022-12-31 | $160.25 Million | -10.60% |
| 2021-12-31 | $179.25 Million | +85.95% |
| 2020-12-31 | $96.40 Million | +344.66% |
| 2019-12-31 | $21.68 Million | -- |